Literature DB >> 32083157

Progressive brainstem pathology in motor neuron diseases: Imaging data from amyotrophic lateral sclerosis and primary lateral sclerosis.

Peter Bede1, Rangariroyashe H Chipika1, Eoin Finegan1, Stacey Li Hi Shing1, Kai Ming Chang1,2, Mark A Doherty3, Jennifer C Hengeveld3, Alice Vajda3, Siobhan Hutchinson4, Colette Donaghy5, Russell L McLaughlin3, Orla Hardiman1.   

Abstract

A standardised, single-centre, longitudinal imaging protocol was used to evaluate longitudinal brainstem alterations in 100 patients with amyotrophic lateral sclerosis (ALS) with reference to 33 patients with primary lateral sclerosis (PLS), 30 patients with frontotemporal dementia (FTD) and 100 healthy controls. "Brainstem pathology in amyotrophic lateral sclerosis and primary lateral sclerosis: A longitudinal neuroimaging study" [1] ALS patients were scanned twice; 4 months apart. T1-weighted imaging data were acquired on a 3 T Philips Achieva MRI system, using a 3D Inversion Recovery prepared Spoiled Gradient Recalled echo (IR-SPGR) sequence. Raw MRI data underwent meticulous quality control before pre-processing. A Bayesian segmentation algorithm was utilised to parcellate the brainstem into the medulla oblongata, pons and mesencephalon before estimating the volume of each segment. Vertex-based shape analyses were carried out to characterise anatomical patterns of atrophy. Brainstem volume loss in ALS was dominated by medulla oblongata atrophy, but significant pontine pathology was also detected. Brainstem volume reductions were more significant in PLS than in ALS after correcting for demographic variables and total intracranial volume. Shape analyses revealed bilateral 'flattening' of the medullary pyramids in ALS compared to healthy controls. Our data demonstrate that computational neuroimaging readily detects brainstem pathology in vivo in both amyotrophic lateral sclerosis and primary lateral sclerosis.
© 2020 The Authors.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Brainstem; Frontotemporal dementia; Magnetic resonance imaging; Medulla oblongata; Mesencephalon; Pons; Primary lateral sclerosis

Year:  2020        PMID: 32083157      PMCID: PMC7016370          DOI: 10.1016/j.dib.2020.105229

Source DB:  PubMed          Journal:  Data Brief        ISSN: 2352-3409


Specifications Table Volumetric brainstem data in ALS and PLS reveal medulla oblongata and pons atrophy compared to healthy and disease controls The dataset provides evidence of phenotype-specific brainstem profiles in motor neuron diseases and is consistent with post mortem studies, pathological TDP-43 staging systems, and the clinical profile of the phenotypes. The presented data demonstrate that ALS-specific imaging signatures can be captured in the brainstem based on T1-weighted datasets alone. This dataset may be useful for biomarker development for pharmaceutical trials in motor neuron diseases.

Data

Despite pathognomonic bulbar involvement in motor neuron diseases [[2], [3], [4]], the majority of imaging studies in ALS and PLS focus on cortical and spinal cord signatures [[5], [6], [7], [8], [9]]. In this dataset we present the volumetric brainstem profile of 100 patients with amyotrophic lateral sclerosis (ALS), 33 patients with primary lateral sclerosis (PLS), 30 patients with frontotemporal dementia (FTD), and 100 age-matched healthy controls (HC) [1] (Table 1). Relevant demographic (age, gender, education and handedness) and clinical (ALSFRS-r) characteristics [10,11] are presented in the companion article [1]. Raw volumetric data for each brainstem segment are available online at Mendeley Data; https://doi.org/10.17632/4t8c4bmw5p.3 Longitudinal brainstem changes in ALS [12] are presented in boxplots (Fig. 1). Reference volumetric data are shown for PLS patients [13], disease controls [14,15] and healthy controls [16] to aid the interpretation of ALS-associated brainstem changes. Based on estimated marginal means corrected for age, gender, total intracranial volumes and education, the comparative profile of the study groups are further illustrated in radar plots with reference to healthy controls (Fig. 2). Focal atrophy patterns are presented as three-dimensional vertex projections (Fig. 3).
Table 1

Data categories and measures.

Data categoriesSpecific measures
Segmental brainstem volumesMedulla oblongata volume (mm3)
Pons volume (mm3)
Mesencephalon volume (mm3)
Vertex contrast between ALS patients and healthy controlsVertex locations of individual participants are projected on the surface of an average brainstem template as scalar values. Permutation based non-parametric statistics were used for group comparisons including age, gender and education. Resulting statistical maps are displayed on 3D mesh templates to showcase focal shape deformations.

ALS = amyotrophic lateral sclerosis; ALSFRS-R = amyotrophic lateral sclerosis functional rating scale-revised; PLS = Primary lateral sclerosis.

Fig. 1

The comparative volumetric brainstem profile of patients with amyotrophic lateral sclerosis at time-point 1 (ALST1), patients with amyotrophic lateral sclerosis at time-point 2 (ALST2), frontotemporal dementia (FTD), healthy controls (HC) and patients with primary lateral sclerosis (PLS).

Fig. 2

The segmental brainstem profile of ALS, PLS and FTD with reference to healthy controls. 100% represents the estimated marginal mean of healthy controls for each structure. Estimated marginal means of volumes were calculated with the following values Age = 59.59, Gender = 1.43, Education = 13.63, TIV = 1435355.28.

Fig. 3

Anatomical patterns of atrophy in ALS compared to healthy controls based on vertex-analyses after corrections for demographic variables. Top: Vertex analyses; brainstem mesh is shown in blue and shape deformations are highlighted in orange at p < 0.05 FWE Bottom: Surface-based vertex analyses; the brainstem mesh template is shown in red.

Data categories and measures. ALS = amyotrophic lateral sclerosis; ALSFRS-R = amyotrophic lateral sclerosis functional rating scale-revised; PLS = Primary lateral sclerosis. The comparative volumetric brainstem profile of patients with amyotrophic lateral sclerosis at time-point 1 (ALST1), patients with amyotrophic lateral sclerosis at time-point 2 (ALST2), frontotemporal dementia (FTD), healthy controls (HC) and patients with primary lateral sclerosis (PLS). The segmental brainstem profile of ALS, PLS and FTD with reference to healthy controls. 100% represents the estimated marginal mean of healthy controls for each structure. Estimated marginal means of volumes were calculated with the following values Age = 59.59, Gender = 1.43, Education = 13.63, TIV = 1435355.28. Anatomical patterns of atrophy in ALS compared to healthy controls based on vertex-analyses after corrections for demographic variables. Top: Vertex analyses; brainstem mesh is shown in blue and shape deformations are highlighted in orange at p < 0.05 FWE Bottom: Surface-based vertex analyses; the brainstem mesh template is shown in red.

Experimental design, materials, and methods

This protocol was approved by the institutional ethics committee and each participant provided informed consent. Recruitment, anonymisation and data management procedures followed institutional and EU data handling guidelines (GDPR). Patients were recruited from a national motor neuron disease clinic to participate in a standardised imaging protocol [8]. Participating ALS patients were diagnosed according to the El Escorial research criteria, PLS patients were diagnosed according to the Gordon criteria and FTD patients according to the Rascovsky criteria [17]. The study was designed to characterise brainstem degeneration in ALS and PLS with a view to identify distinguishing imaging characteristics for diagnostic classification applications [18,19]. T1-weighted images were acquired with a spatial resolution of 1 × 1 × 1mm and field of view of 256 × 256 × 160 mm using a 3D Inversion Recovery prepared Spoiled Gradient Recalled echo (IR-SPGR) sequence; repetition time (TR) = 8.5 ms, echo time (TE) = 3.9 ms, Inversion time (TI) = 1060 ms, flip angle = 8°, SENSE factor = 1.5. Whole brainstem volumes and total intracranial volumes (TIV) were estimated using FSL-FIRST [20] of the FMRIB's Software Library (FSL) [7,14]. The brainstem of each participant was further segmented into the medulla oblongata, pons, and mesencephalon using a Bayesian parcellation algorithm implemented in version 6.0 of the FreeSurfer image analysis suite. Analyses of covariance (ANCOVA) were used to explore intergroup volumetric differences using age, education, gender and TIV as covariates [11]. To illustrate disease-specific volumetric traits in ALS and PLS, the estimated marginal mean of each segment was plotted on a radar chart with reference to healthy controls. As volumetric profiling only detects global volume reductions, additional vertex analyses were performed to characterise focal shape deformations in ALS compared to healthy controls. FMRIB's subcortical segmentation and registration tool FIRST was used for shape analyses to map surface-projected atrophy patterns in the brainstem. ALS patients at their second time point exhibited considerable bilateral flattening of the medullary pyramids above the pyramidal decussation (Fig. 3).

Specifications Table

SubjectNeuroscience (Neurology)
Specific subject areaNeurology
Type of dataRaw volumetric data, Box plots, Radar graph,3D anatomical figures
How data were acquiredImaging data were acquired on a Philips Achieva 3T MRI scanner (Philips Medical Systems, Best, The Netherlands) with an 8-channel head coil.
Data formatRaw volumetric brainstem characteristics; medulla oblongata, pons and mesencephalon volume profiles
Parameters for data collection3D–T1-weighted sequence: spatial resolution: 1 × 1x1mm, Field of view: 256 × 256 × 160 mm, TR/TE = 8.5/3.9 ms, TI = 1060 ms, flip angle = 8°, SENSE factor = 1.5.
Description of data collectionThe protocol, consent forms, recruitment procedures, and data management were approved by the institutional ethics committee. All participants provided informed consent prior to inclusion.Participating ALS patients were diagnosed according to the El Escorial research criteria, PLS patients were diagnosed according to the Gordon criteria, FTD patients were diagnosed according to the Rascovsky criteria. MRI data were acquired on a 3 T Philips Achieva system with uniform pulse sequence settings and anonymised.
Data source locationInstitution: Computational neuroimaging group, Trinity Biomedical Sciences Institute, Trinity College DublinCity/Town/Region: DublinCountry: Ireland
Data accessibilityRaw brainstem volumes and segmental volumetric profiles have been uploaded to ‘Mendeley Data’ https://doi.org/10.17632/4t8c4bmw5p.3
Related research articleAuthors: Peter Bede, Rangariroyashe H. Chipika, Eoin Finegan, Stacey Li Hi Shing, Mark A. Doherty, Jennifer C. Hengeveld, Alice Vajda, Siobhan Hutchinson, Colette Donaghy, Russell L. McLaughlin, Orla HardimanTitle: Brainstem pathology in amyotrophic lateral sclerosis and primary lateral sclerosis: a longitudinal neuroimaging studyJournal: Neuroimage Clinicalhttps://doi.org/10.1016/j.nicl.2019.102054
Value of the Data

Volumetric brainstem data in ALS and PLS reveal medulla oblongata and pons atrophy compared to healthy and disease controls

The dataset provides evidence of phenotype-specific brainstem profiles in motor neuron diseases and is consistent with post mortem studies, pathological TDP-43 staging systems, and the clinical profile of the phenotypes.

The presented data demonstrate that ALS-specific imaging signatures can be captured in the brainstem based on T1-weighted datasets alone.

This dataset may be useful for biomarker development for pharmaceutical trials in motor neuron diseases.

  19 in total

1.  Revisiting the pathoanatomy of pseudobulbar affect: mechanisms beyond corticobulbar dysfunction.

Authors:  Peter Bede; Eoin Finegan
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2017-11-02       Impact factor: 4.092

2.  Connectivity-based characterisation of subcortical grey matter pathology in frontotemporal dementia and ALS: a multimodal neuroimaging study.

Authors:  Peter Bede; Taha Omer; Eoin Finegan; Rangariroyashe H Chipika; Parameswaran M Iyer; Mark A Doherty; Alice Vajda; Niall Pender; Russell L McLaughlin; Siobhan Hutchinson; Orla Hardiman
Journal:  Brain Imaging Behav       Date:  2018-12       Impact factor: 3.978

Review 3.  The changing landscape of motor neuron disease imaging: the transition from descriptive studies to precision clinical tools.

Authors:  Peter Bede; Giorgia Querin; Pierre-François Pradat
Journal:  Curr Opin Neurol       Date:  2018-08       Impact factor: 5.710

4.  Neuroimaging patterns along the ALS-FTD spectrum: a multiparametric imaging study.

Authors:  Taha Omer; Eoin Finegan; Siobhan Hutchinson; Mark Doherty; Alice Vajda; Russell L McLaughlin; Niall Pender; Orla Hardiman; Peter Bede
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2017-05-31       Impact factor: 4.092

5.  Hippocampal pathology in amyotrophic lateral sclerosis: selective vulnerability of subfields and their associated projections.

Authors:  Foteini Christidi; Efstratios Karavasilis; Michail Rentzos; Georgios Velonakis; Vasiliki Zouvelou; Sofia Xirou; Georgios Argyropoulos; Ioannis Papatriantafyllou; Varvara Pantolewn; Panagiotis Ferentinos; Nikolaos Kelekis; Ioannis Seimenis; Ioannis Evdokimidis; Peter Bede
Journal:  Neurobiol Aging       Date:  2019-09-23       Impact factor: 4.673

6.  Survival prediction in Amyotrophic lateral sclerosis based on MRI measures and clinical characteristics.

Authors:  Christina Schuster; Orla Hardiman; Peter Bede
Journal:  BMC Neurol       Date:  2017-04-17       Impact factor: 2.474

Review 7.  Clinical Measures of Bulbar Dysfunction in ALS.

Authors:  Yana Yunusova; Emily K Plowman; Jordan R Green; Carolina Barnett; Peter Bede
Journal:  Front Neurol       Date:  2019-02-19       Impact factor: 4.003

Review 8.  Pathological Crying and Laughing in Motor Neuron Disease: Pathobiology, Screening, Intervention.

Authors:  Eoin Finegan; Rangariroyashe H Chipika; Stacey Li Hi Shing; Orla Hardiman; Peter Bede
Journal:  Front Neurol       Date:  2019-03-21       Impact factor: 4.003

9.  The clinical and radiological profile of primary lateral sclerosis: a population-based study.

Authors:  Eoin Finegan; Rangariroyashe H Chipika; Stacey Li Hi Shing; Mark A Doherty; Jennifer C Hengeveld; Alice Vajda; Colette Donaghy; Russell L McLaughlin; Niall Pender; Orla Hardiman; Peter Bede
Journal:  J Neurol       Date:  2019-07-19       Impact factor: 4.849

10.  Brainstem pathology in amyotrophic lateral sclerosis and primary lateral sclerosis: A longitudinal neuroimaging study.

Authors:  Peter Bede; Rangariroyashe H Chipika; Eoin Finegan; Stacey Li Hi Shing; Mark A Doherty; Jennifer C Hengeveld; Alice Vajda; Siobhan Hutchinson; Colette Donaghy; Russell L McLaughlin; Orla Hardiman
Journal:  Neuroimage Clin       Date:  2019-10-24       Impact factor: 4.881

View more
  4 in total

Review 1.  The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development.

Authors:  Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-05       Impact factor: 3.978

2.  Extra-motor cerebral changes and manifestations in primary lateral sclerosis.

Authors:  Eoin Finegan; Stacey Li Hi Shing; Rangariroyashe H Chipika; Kai Ming Chang; Mary Clare McKenna; Mark A Doherty; Jennifer C Hengeveld; Alice Vajda; Niall Pender; Colette Donaghy; Siobhan Hutchinson; Russell L McLaughlin; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-07       Impact factor: 3.978

3.  Medulla oblongata volume as a promising predictor of survival in amyotrophic lateral sclerosis.

Authors:  Giammarco Milella; Alessandro Introna; Alma Ghirelli; Domenico Maria Mezzapesa; Ucci Maria; Eustachio D'Errico; Angela Fraddosio; Isabella Laura Simone
Journal:  Neuroimage Clin       Date:  2022-04-22       Impact factor: 4.891

4.  Cortical progression patterns in individual ALS patients across multiple timepoints: a mosaic-based approach for clinical use.

Authors:  Marlene Tahedl; Rangariroyashe H Chipika; Jasmin Lope; Stacey Li Hi Shing; Orla Hardiman; Peter Bede
Journal:  J Neurol       Date:  2021-01-05       Impact factor: 4.849

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.